<DOC>
	<DOC>NCT01754688</DOC>
	<brief_summary>The investigators hypothesize that a new BIND (Bilirubin Induced Neurologic Dysfunction) scoring method adapted for the developing world (BIND II, developed by our team for use by health care workers), with additional modifications for community use (the community BIND, C-BIND), will improve the ability to identify infants with ABE and to distinguish ABE from other common causes of neonatal morbidity and mortality compared to currently available survey tools.</brief_summary>
	<brief_title>Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Kernicterus</mesh_term>
	<mesh_term>Bilirubin</mesh_term>
	<criteria>Subjects will be eligible to participate in the study if all of the following conditions exist: 1. At time of birth, neonates who are ≥ 35 weeks gestational age or ≥ 2250 grams if gestational age unavailable. 2. ≤ 14 days old 3. Parent or guardian has given consent for the infant to participate 1. Infants with a condition requiring urgent referral to another facility for treatment not available at the hospital study site. 2. Infants being admitted for a surgical procedure only without an underlying medical illness. 3. Infants who have a condition that requires no blood draws for treatment of their problem and only reason for blood draw would be study enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>